Quantcast
Home / Practice Areas / Business and Civil Practice / Merck settles Vytorin shareholder class action suit

Merck settles Vytorin shareholder class action suit

Merck will pay $5.1 million in attorney fees and institute corporate reforms under the terms of a settlement of a shareholder class action concerning the alleged suppression of negative clinical test results for the blockbuster anti-cholesterol drug Vytorin.